AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
REGENXBIO Inc.
Study ID
NCT05683379
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
0 Years - 25 Years
Healthy Volunteers
Not accepted

Interventions

  • AAV8 DetectCDx — DIAGNOSTIC_TEST
    An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.

Study Details

This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).

Key Dates

Start date
Dec 20, 2022
Status verified
Nov 2025
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
200 participants (estimated)

Primary Outcome Measure

Prevalence of anti-AAV8 antibodies in patients with DMD [ Time Frame: 90 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Rare Disease ResearchAtlantaGeorgia30329
Lily Goggans
[email protected]
470-600-9134
Maureen Ikpeoha
[email protected]
470-666-1884
Han Phan, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Atlanta, GA

By condition
Duchenne muscular dystrophy
By specialty
Pediatrics
By research site
Rare Disease Research· Atlanta, GA

Related Studies